• All Share : 51637.28
    DOWN -1.13%
    Top40 - (Tradeable) : 46327.67
    DOWN -1.17%
    Financial 15 : 16388.16
    DOWN -0.91%
    Industrial 25 : 71595.92
    DOWN -0.93%
    Resource 10 : 26210.79
    DOWN -3.50%

  • ZAR/USD : 14.4066
    UP 0.01%
    ZAR/GBP : 21.6241
    UP 0.02%
    ZAR/EUR : 15.2586
    UP 0.03%
    ZAR/JPY : 0.1168
    UP 0.69%
    ZAR/AUD : 10.352
    DOWN -0.10%

  • Gold US$/oz : 1057.46
    Platinum US$/oz : 852.53
    Silver US$/oz : 14.1
    Palladium US$/oz : 551
    Brent Crude : 45.46

  • All data is delayed by 15 min. Data supplied by Profile Data
    Hover cursor over this ticker to pause.

Sun Nov 29 19:43:24 SAST 2015

South Africa awards R5.9 billion HIV drugs supply contracts

Reuters | 29 November, 2012 14:26
HIV infecting a cell (blue). File illustration.
Image by: Gallo Imges/Thinkstock

South Africa on Thursday awarded a R5.9 billion contract to supply life-prolonging HIV medicine to 12 international and domestic firms, to deal with its biggest health problem.

Companies that include Aspen Pharmacare, Abbott Laboratories and Adcock Ingram would share the contract, the health department said.

The 5.9 billion rand ($667 million) contract, effective from April next year, aims to increase the number of people on treatment by nearly 50 percent, to 2.5 million next year.

South Africa has nearly 6 million people infected with HIV -- one of the heaviest caseloads in the world. It also has one of largest treatment programmes.

But drug makers are unlikely to rake in big profits from the government award, analysts have ssaid, given the stiff competition in the bidding.

The health department said it saved 2.2 billion rand on the new contract, which it initially expected it would cost 8.1 billion rand.

Aspen Pharmacare, the country's biggest generic drugs maker, was awarded 20 percent of the contract while its closest domestic rival, Adcock Ingram was given 14 percent, the health department said.

Other contracts winners included Chicago-based Abbott Laboratories with 8.1 percent, and domestic firm Cipla Medpro with 9 percent.


If you have an opinion you would like to share on this article, please send us an e-mail to the Times LIVE iLIVE team. In the mean time, click here to view the Times LIVE iLIVE section.